← Back to Screener
Cue Biopharma, Inc. (CUE)
Price$0.85
Favorite Metrics
Price vs S&P 500 (26W)-32.59%
Price vs S&P 500 (4W)118.40%
Market Capitalization$82.97M
All Metrics
Book Value / Share (Quarterly)$0.27
P/TBV (Annual)3.15x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)180.09%
Cash Flow / Share (Quarterly)$-0.23
Price vs S&P 500 (YTD)94.62%
Net Profit Margin (TTM)-96.85%
EPS (TTM)$-0.31
10-Day Avg Trading Volume46.43M
EPS Excl Extra (TTM)$-0.31
Revenue Growth (5Y)54.20%
EPS (Annual)$-0.28
ROI (Annual)-98.09%
Net Profit Margin (5Y Avg)-1199.06%
Cash / Share (Quarterly)$0.28
Revenue Growth QoQ (YoY)1292.26%
ROA (Last FY)-63.02%
Revenue Growth TTM (YoY)195.75%
EBITD / Share (TTM)$-0.28
ROE (5Y Avg)-123.60%
Operating Margin (TTM)-96.67%
Cash Flow / Share (Annual)$-0.23
P/B Ratio3.14x
P/B Ratio (Quarterly)1.05x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)2.06x
ROA (TTM)-77.77%
EPS Incl Extra (Annual)$-0.28
Current Ratio (Annual)2.74x
Quick Ratio (Quarterly)2.64x
3-Month Avg Trading Volume6.56M
52-Week Price Return-22.18%
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$1.95
P/S Ratio (Annual)3.02x
Asset Turnover (Annual)0.65x
52-Week High$1.03
Operating Margin (5Y Avg)-1208.72%
EPS Excl Extra (Annual)$-0.28
CapEx CAGR (5Y)-21.66%
Tangible BV CAGR (5Y)1.35%
26-Week Price Return-23.84%
Quick Ratio (Annual)2.64x
13-Week Price Return77.77%
Total Debt / Equity (Annual)0.03x
Current Ratio (Quarterly)2.74x
Enterprise Value$56.526
Revenue / Share Growth (5Y)21.43%
Asset Turnover (TTM)0.80x
Book Value / Share Growth (5Y)-36.26%
Revenue / Employee (Annual)$1
Pretax Margin (Annual)-95.03%
Cash / Share (Annual)$0.28
3-Month Return Std Dev234.65%
Net Income / Employee (TTM)$-1
ROE (Last FY)-100.64%
EPS Basic Excl Extra (Annual)$-0.28
Receivables Turnover (TTM)8.46x
Total Debt / Equity (Quarterly)0.03x
EPS Incl Extra (TTM)$-0.31
Receivables Turnover (Annual)8.46x
ROI (TTM)-146.30%
P/S Ratio (TTM)3.02x
Pretax Margin (5Y Avg)-1198.04%
Revenue / Share (Annual)$0.29
Tangible BV / Share (Annual)$3.69
Price vs S&P 500 (52W)-57.28%
Year-to-Date Return98.75%
5-Day Price Return28.35%
EPS Normalized (Annual)$-0.28
ROA (5Y Avg)-76.57%
Net Profit Margin (Annual)-96.85%
Month-to-Date Return163.57%
Cash Flow / Share (TTM)$-1.17
EBITD / Share (Annual)$-0.28
Operating Margin (Annual)-96.67%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-106.80%
LT Debt / Equity (Quarterly)0.01x
EPS Basic Excl Extra (TTM)$-0.31
P/TBV (Quarterly)4.48x
P/B Ratio (Annual)1.05x
Pretax Margin (TTM)-95.03%
Book Value / Share (Annual)$0.27
Price vs S&P 500 (13W)74.91%
Beta2.70x
Revenue / Share (TTM)$0.25
ROE (TTM)-165.19%
52-Week Low$0.17
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.17
4.17
4.00
4.00
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CUECue Biopharma, Inc. | 3.02x | 195.75% | — | — | $0.85 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Cue Biopharma is a clinical-stage biopharmaceutical company developing a proprietary class of biologics designed to selectively modulate the immune system for treating cancer and autoimmune diseases. The company's pipeline includes CUE-101 (alone and in combination with Pembrolizumab), CUE-102, CUE-103, and other candidates leveraging its immune modulation platform.